Hepatocyte Nuclear Factor 1-Alpha (HNF1A) is a critical homeodomain-containing transcription factor that regulates the expression of several liver-specific genes, including those encoding PCSK9, DPP4, albumin, and various transporters. Mutations in the HNF1A gene are the primary cause of Maturity-Onset Diabetes of the Young Type 3 (MODY3), while dysregulation of HNF1A expression is increasingly implicated in pancreatic ductal adenocarcinoma (PDAC) and hepatocellular carcinoma (HCC). Developing therapeutics targeting HNF1A—ranging from small molecule transcriptional modulators and molecular glues to gene therapies—requires highly characterized, sequence-verified reagents to overcome the challenges of intracellular targeting and structural homology.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HNF1A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HNF1A Recombinant Protein (WT & MODY3 Mutants) High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spec. E. coli/HEK293 expressed options. |
View HNF1A Products |
| Gene Delivery | HNF1A Promise-ORF / Lentivirus Full-length WT or mutant ORF under CMV/EF1a promoters for stable cell line generation. |
View HNF1A Products |
| Benchmark Ab | Anti-HNF1A Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and ChIP assays. |
View HNF1A Products |
| Validator | HNF1A siRNA Set Target-specific knockdown verification in hepatic and pancreatic cell lines. |
View HNF1A Products |
| Related Target A | PCSK9 Direct downstream target of HNF1A; crucial for validating transcriptional modulation of cholesterol metabolism. |
View PCSK9 Products |
| Related Target B | DPP4 Downstream metabolic target regulated by HNF1A; relevant for MODY3 and type 2 diabetes research. |
View DPP4 Products |
| Related Target C | HNF1B Close structural homolog (HNF1-beta); essential for off-target selectivity screening. |
View HNF1B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homolog Off-Target Screening (HNF1B) | Highly purified HNF1A and HNF1B proteins available for comparative DNA-binding and SPR assays. |
| MODY3 Mutation Modeling | Custom mutant recombinant proteins (e.g., P291fs, R272H) with verified molecular weights. |
| In vitro Transcriptional Activity Assays | Lentivirus premade particles for robust, stable expression of HNF1A in reporter cell lines. |
| Lack of Validated Knockdown Controls | Sequence-verified siRNA sets included for specific target validation. |
Live HNF1A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for HNF1A is bifurcated into metabolic disorders and oncology. In endocrinology, the focus is on correcting HNF1A haploinsufficiency in MODY3 patients using small-molecule correctors, sulfonylureas, or gene-editing modalities. In oncology, particularly pancreatic and liver cancers, HNF1A acts as a master regulator of cell differentiation and stemness, making it a key target for transcriptional inhibitors and targeted protein degradation (PROTACs/molecular glues). As first-generation indirect therapies reach maturity, the next wave of R&D is shifting toward direct modulation of HNF1A-DNA binding and recruiting E3 ligases for targeted degradation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Transcription Modulators) | Academic Medical Centers, Biotech Startups | MODY3, Type 2 Diabetes | DNA-binding assays (Requires pure, native-conformation HNF1A recombinant protein) |
| Targeted Protein Degradation (PROTACs/Glues) | Oncology-focused Biopharma | Pancreatic Cancer, HCC | Ternary complex formation assays (Requires high-purity, sequence-verified HNF1A protein) |
| Gene Therapy / mRNA | Gene Therapy Developers | MODY3 (HNF1A deficiency) | Functional rescue assays (Requires HNF1A Lentivirus for stable expression validation) |